Let's innovate in cancer R&D - together.
Join us at BIO-Europe 2025 in Vienna this November and discover how Indivumed is shaping the future of precision oncology. Our team is ready to connect, share insights, and explore parterning opportunities to co-create first-in-class cancer therapeutics.
)
Advancing first-in-class cancer therapeuticsA pipeline of therapeutically novel targets
We’re building an innovative pipeline of small molecules and biologics. Powered by our patient-centric platform - connecting molecular and clinical data – our approach to target identification, validation, and drug discovery is rooted in disease understanding. This foundation enables us to generate novel insights and discover innovative targets.
)
Partner with usCollaboration that drives innovation
Science alone isn’t enough. Bringing cancer therapeutics to patients requires the right partners. Do you want to learn more about our small molecule program IN-2401, a first-in-class opportunity in colorectal cancer? Or explore our work on surfaceome tumor antigens? We're also ready to co-create entirely new pipelines from scratch.
On stage at Bio-Europe 2025Two panel discussions shaping the future of biopharma
Our CEO and our CBO will join other industry experts on stage to share perspectives on the trends redefining partnerships and innovation. From M&A strategies to the evolving role of strategic services, these sessions bring together thought leaders to explore what’s next for biopharma.
)
Join the panel discussion
“The rhythms of M&A and business development in 2025 and beyond”
)
Industry insights with leading experts
“Is the blend of strategic services the secret ingredient to biotech success?”
Ready to connect?Let’s shape the future of cancer treatment together
From our dynamic pipeline of small molecules and biologics to flexible partnering models and thought leadership at BIO-Europe, Indivumed is committed to driving innovation in oncology. Explore how we can collaborate to bring first-in-class therapeutics to patients faster.